Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform
Aim. Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. Material and Methods. A retrospective, observational study using the I-Macula Web platform. Results. Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were anal...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2017/5601786 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559915721293824 |
|---|---|
| author | Massimo Nicolò Monica Bonetto Raffaella Rosa Donatella Musetti Maria Musolino Carlo Enrico Traverso Mauro Giacomini |
| author_facet | Massimo Nicolò Monica Bonetto Raffaella Rosa Donatella Musetti Maria Musolino Carlo Enrico Traverso Mauro Giacomini |
| author_sort | Massimo Nicolò |
| collection | DOAJ |
| description | Aim. Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. Material and Methods. A retrospective, observational study using the I-Macula Web platform. Results. Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p=0.0235) and central macular thickness (p<0.0001). The mean change in visual acuity was 8.9 letters. Twenty-seven eyes underwent DEX implant (n=62; mean: 2.29) only. Of these, 8, 4, 14, and 1 eyes underwent 1, 2, 3, and 4 DEX implants, respectively. The remaining 10 eyes were also injected with ranibizumab (n=49; mean: 4.9). At 12 months, 12 eyes (32.5%) presented a dry macula, whereas the remaining 25 eyes (67.5%) still had macular edema. Mean interval between the first and second treatment (T1) and between the second and third treatment (T2) were 5.15 and (T2) 3.7 months, respectively. Where only DEX implants were received, T1 and T2 was 5.1 and 4.9 months, respectively. Conclusions. This study confirms that DEX implants and/or anti-VEGF drugs improve visual acuity and central macular thickness in patients affected by RVO. |
| format | Article |
| id | doaj-art-907873e81590440aa0f1b313b76eb3ac |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-907873e81590440aa0f1b313b76eb3ac2025-02-03T01:28:50ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/56017865601786Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web PlatformMassimo Nicolò0Monica Bonetto1Raffaella Rosa2Donatella Musetti3Maria Musolino4Carlo Enrico Traverso5Mauro Giacomini6Clinica Oculistica-DINOGMI, Università di Genova and Italy Ospedale Policlinico San Martino, Genoa, ItalyHealthropy SRL, Genoa, ItalyClinica Oculistica-DINOGMI, Università di Genova and Italy Ospedale Policlinico San Martino, Genoa, ItalyClinica Oculistica-DINOGMI, Università di Genova and Italy Ospedale Policlinico San Martino, Genoa, ItalyClinica Oculistica-DINOGMI, Università di Genova and Italy Ospedale Policlinico San Martino, Genoa, ItalyClinica Oculistica-DINOGMI, Università di Genova and Italy Ospedale Policlinico San Martino, Genoa, ItalyHealthropy SRL, Genoa, ItalyAim. Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. Material and Methods. A retrospective, observational study using the I-Macula Web platform. Results. Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p=0.0235) and central macular thickness (p<0.0001). The mean change in visual acuity was 8.9 letters. Twenty-seven eyes underwent DEX implant (n=62; mean: 2.29) only. Of these, 8, 4, 14, and 1 eyes underwent 1, 2, 3, and 4 DEX implants, respectively. The remaining 10 eyes were also injected with ranibizumab (n=49; mean: 4.9). At 12 months, 12 eyes (32.5%) presented a dry macula, whereas the remaining 25 eyes (67.5%) still had macular edema. Mean interval between the first and second treatment (T1) and between the second and third treatment (T2) were 5.15 and (T2) 3.7 months, respectively. Where only DEX implants were received, T1 and T2 was 5.1 and 4.9 months, respectively. Conclusions. This study confirms that DEX implants and/or anti-VEGF drugs improve visual acuity and central macular thickness in patients affected by RVO.http://dx.doi.org/10.1155/2017/5601786 |
| spellingShingle | Massimo Nicolò Monica Bonetto Raffaella Rosa Donatella Musetti Maria Musolino Carlo Enrico Traverso Mauro Giacomini Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform Journal of Ophthalmology |
| title | Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform |
| title_full | Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform |
| title_fullStr | Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform |
| title_full_unstemmed | Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform |
| title_short | Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform |
| title_sort | real life management of patients with retinal vein occlusion using i macula web platform |
| url | http://dx.doi.org/10.1155/2017/5601786 |
| work_keys_str_mv | AT massimonicolo reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform AT monicabonetto reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform AT raffaellarosa reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform AT donatellamusetti reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform AT mariamusolino reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform AT carloenricotraverso reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform AT maurogiacomini reallifemanagementofpatientswithretinalveinocclusionusingimaculawebplatform |